What the business is, and whether it's a good one at a fair price.
Provides contract research and laboratory testing services to pharmaceutical, food and environmental, and electronics companies. Operations run out of a ~200,000 sq ft Genome Valley lab campus that is ~60% occupied. The pharma contract research arm is delivering consistent year-on-year growth, while the clinical research arm is showing early signs of recovery after prior-year challenges. Biologics contract research and development services were recently launched, with a first customer order already secured, though meaningful P&L contribution is only expected from the third year onwards. Food and environmental testing is under pressure from Middle East trade disruption, with the business pivoting toward domestic clients. Electronics and electrical testing has stabilised after prior leadership issues and benefits from a 15.19% YoY increase in the defence budget. Employees are the largest cost at 28.1% of revenue, followed by materials at 19.8% and other operating expenses at 17.3%.
Measured from the filed financials, judged against its Healthcare Services peers · as of FY24 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from VIMTA LABS LIMITED's filed financials and exchange disclosures
VIMTA LABS LIMITED is a Healthcare Services company listed on NSE and BSE, trading under the symbol VIMTALABS.
Yes. Over the trailing twelve months VIMTA LABS LIMITED reported a net profit of ₹61 Cr on revenue of ₹336 Cr.
Yes. The dividend yield is 0.16% at the current price. It paid out 11% of its profit as dividend in FY24.
Effectively yes. It holds ₹3 Cr more cash than debt. Debt stands at 0.06× equity.
On trailing P/E, VIMTA LABS LIMITED ranks 29 of 68 in Healthcare Services — cheaper than 58% of them, against an industry median of 31.2×. This is a position, not a valuation judgement.
On a typical session VIMTA LABS LIMITED moves 1.53% — that is the median absolute close-to-close move across its last 269 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by VIMTA LABS LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.